HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Torregrosa, S. Articles by Caffarena, J. M. Search for Related Content PubMed PubMed Citation Articles by Torregrosa, S. Articles by Caffarena, J. M.

Ann Thorac Surg 1999;68:881-886
© 1999 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Long-term clinical experience with the omnicarbon prosthetic valve

^a Servicio de Cirugía Cardiovascular, Hospital Universitario "La Fé", Valencia, Spain

Address reprint requests to Dr José M. Caffarena, Servício de Cirugía Cardiovascular, Hospital Universitario "La Fé," Avda de Campanar 21, 46009 Valencia, Spain

Background. From February 1985 to December 1994, 781 Omnicarbon valve prostheses were implanted in 647 patients. These were 357 male and 290 female patients with a mean age of 53.5 ± 10.5 years (range, 4 to 78 years). Before operation, 81% of the patients were in New York Heart Association class III or IV, 16% were in class II, and only 3% were in class I.

Methods. There were 227 aortic valve replacements (AVR) (35%), 286 mitral valve replacements (MVR) (44%), and 134 double-valve replacements (DVR) (21%) (AVR + MVR). Follow-up was 96.3% complete and consisted of 2,746 patient-years (mean follow-up, 4.6 years, and maximum follow-up, 10.7 years).

Results. Hospital mortality rates were 7.0% for AVR, 8.0% for MVR, and 8.2% for DVR. The annualized rate of anticoagulant-related hemorrhage was 0.8% per patient-year, and thromboembolism occurred at a rate of 0.7% per patient-year. No structural failure was observed during 10-year follow-up. Twenty-one instances of nonstructural dysfunction (two, pannus growth, and 19, dehiscence) of the Omnicarbon valve occurred in 20 patients, an incidence of 0.8% per patient-year. Hemolytic anemia was observed only in the presence of valvular dehiscence (6 of 19). Eight patients (0.3% per patient-year) had development of prosthetic valve endocarditis (4, AVR; 2, MVR; and 2 DVR). At the end of 10 years of follow-up, 91% of the survivors were in New York Heart Association class I or II. The overall survival rate at 10 years was 82.5% ± 2.6% (85.0% ± 3.9%, AVR; 81.0% ± 4.1%, MVR; and 82.5% ± 2.6%, DVR). Considering only valve-related deaths, the survival rate at 10 years was 91.9% ± 2.4% (90.0% ± 2.7%, AVR; 93.1% ± 3.8%, MVR; and 90.0% ± 1.8%, DVR).

Conclusions. Clinical results over a 10-year follow-up are excellent with the Omnicarbon prosthesis.

This article has been cited by other articles:

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement , January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				T. Gudbjartsson, S. Aranki, and L. H. Cohn Mechanical/Bioprosthetic Mitral Valve Replacement , January 1, 2003; 2(2003): 951 - 986. [Full Text]

				R. W. Baumgartner, A. Frick, C. Kremer, E. Oechslin, E. Russi, J. Turina, and D. Georgiadis Microembolic signal counts increase during hyperbaric exposure in patients with prosthetic heart valves J. Thorac. Cardiovasc. Surg., December 1, 2001; 122(6): 1142 - 1146. [Abstract] [Full Text] [PDF]

				R. A. DeWall, N. Qasim, and L. Carr Evolution of mechanical heart valves Ann. Thorac. Surg., May 1, 2000; 69(5): 1612 - 1621. [Abstract] [Full Text] [PDF]